Oh yee foolish folk that sell on the tails of the Fin Review. MSB was always a risky proposition. These are the times to buy, not to sell.
Great levels for new holders, poor for long term holders including myself. The pathways are there. If Novartis sign an amended agreement (and they would have walked months ago if they were not interested) this goes back to $3 and are fabled writers at the FR are going to look a little silly, as they always do, being six months behind the curve.
MSB Trading 2021 - paradigm shift, page-7453
-
- There are more pages in this discussion • 2,758 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |